Skip to content

Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit

Acceptability of Advanced Chronic Liver Disease Screening by Transient Elstography (Fibroscan ®) in Patients Hospitalised in Psychiatric Unit: a Single Center Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05602870
Acronym
HEPSY
Enrollment
180
Registered
2022-11-02
Start date
2023-03-07
Completion date
2024-01-05
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Chronic Liver Disease, Liver Fibrosis, Psychiatric Disorder, Psychiatric Hospitalization

Keywords

psychiatric disorders, advanced liver disease, alcoholic liver diseases, viral hepatitis, transient elastography (Fibroscan ®)

Brief summary

Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.

Detailed description

Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results. The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit. Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.

Interventions

DIAGNOSTIC_TESTnon invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)

A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adults ≥18 years * having a psychiatric condition and hospitalized in a psychiatry unit of CHU Montpellier , France * patients who lack capacity of consent if legal representative consents * involuntary psychiatric hospitalization, if consent is given

Exclusion criteria

* lack of written consent * Unable to understand nature and objective of the methodology * Pregnant or breast feeding woman * Not affiliated with a French social security

Design outcomes

Primary

MeasureTime frameDescription
acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patientsAt InclusionNumber of patient who have agreed to do fibroscan screening among patient to whom it was offered.

Secondary

MeasureTime frameDescription
prevalence of excessive alcohol or drug consumption in psychiatric patientsAt inclusionNumber of patient with excessive alcohol/drug consumption
prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patientsAt InclusionNumber of patient with excessive alcohol/drug consumption
prevalence of viral hepatitis in psychiatric patientsAt InclusionNumber of patient diagnosed with viral hepatitis B, D, C
Prevalence of advanced liver disease in psychiatric patientsAt inclusionNumber of patient who are diagnosed with advanced liver disease among patient to whom it was offered.
assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology1 to 3 month after inclusionNumber of patients that have actually came to their medical appoint after advanced fibrosis diagnosis
reason for refusal of non invasive evaluation of chronic liver diseaseAt Inclusionrate of reasons of refusal according to reason of hospitalization, sector, duration of hospitalization, time spend in study explaination, patient reflection time
correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients1 to 3 month after inclusionNumber of patients with advanced chronic liver disease among those having risk factors for chronic liver disease

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026